Roxadustat Demystified: The Definitive 2026 Guide to a First-in-Class Anemia Breakthrough
Imagine living with the crushing fatigue of chronic kidney disease (CKD)-related anemia—where every step feels like wading through wet cement, your skin is pale, and your mind is foggy.
For decades, your only option to fight this was a needle: erythropoiesis-stimulating agents (ESAs) injected under your skin or into a vein, often in a hospital or dialysis center.
But what if you could swallow a pill? What if that pill didn’t just mimic the hormone your kidneys once made, but actually coaxed your own body to produce it again—while also unlocking iron stores you didn’t even know you had?
That pill exists. It’s called Roxadustat.
And it’s not just another “me-too” drug. It’s a first-in-class medication that kickstarted an entirely new therapeutic category: the oral hypoxia-inducible factor prolyl hydroxylase inhibitors, or HIF-PHIs.
It has been launched in China, Japan, Germany, the United Kingdom, and dozens of other countries.
It’s racked up blockbuster sales projections, split regulatory agencies, and sparked heated debates in FDA advisory committee meetings.
But amidst the buzz, there’s a lot of confusion—and, frankly, some misinformation. Is it FDA-approved? (The answer is more nuanced than a simple yes or no.)
Is FG-4592 the same thing? Does it cause heart problems or prevent them? How long until your hemoglobin climbs? And why can’t you take it with your morning statin?
This post is your one-stop, no-nonsense masterclass on Roxadustat.
We’re going to dive deep—layer by layer—into the science, clinical data, controversies, practical prescribing tips, and the global supply chain.
Whether you’re a patient weighing your treatment options, a clinician looking for a clear summary of the evidence, a compounding pharmacist, or a pharmaceutical buyer hunting for a reliable Roxadustat API source, you’ve found the most comprehensive resource on the web.
Let’s get started.
What is Roxadustat?
Roxadustat is an orally bioavailable small molecule—a pill, essentially—that belongs to a brand-new class of medications called hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs).
The drug was originally developed by FibroGen (now known as Kyntra Bio) in collaboration with Astellas Pharma and AstraZeneca.
Chemically, its molecular formula is C₁₉H₁₆N₂O₅, with a molecular mass of 352.34 g/mol. The IUPAC name is a mouthful: 2-[(4-hydroxy-1-methyl-7-phenoxyisoquinoline-3-carbonyl)amino]acetic acid.
To understand why Roxadustat is so groundbreaking, you need to appreciate the 2019 Nobel Prize in Physiology or Medicine, awarded to William Kaelin Jr., Sir Peter Ratcliffe, and Gregg Semenza for their work on how cells sense and adapt to oxygen availability—specifically, the hypoxia-inducible factor (HIF) pathway.
Under normal oxygen conditions, enzymes called prolyl hydroxylase domain (PHD) proteins tag HIF for degradation.
Under low oxygen (hypoxia), those PHD enzymes are inhibited, HIF accumulates, and it turns on genes that help your body cope with low oxygen—including the gene for erythropoietin (EPO). This hormone tells your bone marrow to make red blood cells.
Roxadustat is a synthetic molecule that inhibits those PHD enzymes even when oxygen levels are normal. Stabilizing HIF tricks your body into mounting a coordinated, natural erythropoietic response—boosting endogenous EPO production, improving iron absorption, and suppressing hepcidin (a hormone that blocks iron release).
It’s a masterful piece of pharmacological mimicry.
Is Roxadustat the Same as FG-4592?
Yes—unequivocally.
FG-4592 is the original developmental code name for roxadustat.
In the early clinical trial literature, particularly the Phase 2 studies conducted in China, the compound is almost exclusively referred to as FG-4592.
You’ll also encounter it as ASP1517 (Astellas’ internal code) and AZD 9941 (AstraZeneca’s designation).
The United States Adopted Name (USAN) is roxadustat, and the brand name in most markets is Evrenzo.
Regardless of which name you see, they all refer to the same HIF-PH inhibitor molecule: C₁₉H₁₆N₂O₅.
This is critical for clinicians and researchers reviewing the literature.
If you’re reading a paper about FG-4592 and wondering whether it applies to your patient taking Evrenzo, the answer is a resounding yes.
Is Roxadustat FDA-Approved?
Roxadustat is currently NOT FDA-approved for the treatment of anemia in CKD patients in the United States.
In 2021, the FDA’s Cardiovascular and Renal Drugs Advisory Committee voted 13 to 1 against approval for non-dialysis-dependent patients and 12 to 2 against for dialysis-dependent patients, citing safety concerns—chiefly the risk of serious thromboembolic events and inconsistencies in how cardiovascular safety data were adjudicated.
The FDA subsequently issued a Complete Response Letter, demanding an additional clinical trial before it would reconsider the application.
The PDUFA date had originally been set for December 20, 2020, but the extended review resulted in rejection.
Meanwhile, the drug sailed through regulatory agencies in other parts of the world.
The European Medicines Agency (EMA) approved Evrenzo (roxadustat) in 2021 for adults with symptomatic anemia associated with CKD, in both non-dialysis-dependent (NDD) and dialysis-dependent (DD) patients.
In the UK, NICE recommends roxadustat as an option for treating symptomatic anemia associated with CKD in adults with stage 3-5 CKD, no iron deficiency, and not on dialysis at the start of treatment.
Roxadustat is also approved in China (the first country to greenlight it, in December 2018), Japan, Chile, South Korea, and numerous other countries.
As of 2026, roxadustat remains under review in Australia, Brazil, Canada, India, and several other markets.
In the US, it has secured Orphan Drug Designation for myelodysplastic syndromes (MDS), and a Phase 3 protocol for that population has been finalized.
So while American CKD patients cannot yet access roxadustat, the global landscape is vast—and the door for future US approval is not closed.
What Is Roxadustat Used For?
Roxadustat’s approved indications vary slightly by region.
Still, the core use case is consistent: treatment of symptomatic anemia associated with chronic kidney disease (CKD) in adults, encompassing both dialysis-dependent (DD) and non-dialysis-dependent (NDD) patients.
Let’s break down the specific indications and the evidence behind them.
1. Anemia of CKD (Non-Dialysis-Dependent)
In the landmark DOLOMITES trial, a randomized, open-label, active-controlled Phase 3 study, roxadustat was compared head-to-head with darbepoetin alfa in 616 patients with NDD-CKD. The results were striking: roxadustat achieved an 89.5% hemoglobin response rate compared to 78.0% for darbepoetin, meeting the non-inferiority endpoint with a difference of 11.51 percentage points (95% CI 5.66–17.36%). Roxadustat maintained hemoglobin levels for up to 104 weeks, significantly reduced LDL cholesterol, and decreased the need for intravenous iron—all with a comparable safety profile.
2. Anemia of CKD (Dialysis-Dependent)
For patients on hemodialysis or peritoneal dialysis, roxadustat has shown robust efficacy in correcting and maintaining hemoglobin. The Phase 3 ROCKIES, SIERRAS, and HIMALAYAS trials all contributed to the approval in this population. Real-world post-marketing surveillance data from Japan, involving over 2,000 patients, confirmed that most patients reached the target hemoglobin level within 12 weeks.
3. Chemotherapy-Induced Anemia
Clinical development for chemotherapy-induced anemia is underway, with roxadustat being investigated in Phase 3 trials in China. Astellas had previously been developing it for this indication in its licensed territories, but discontinued that program in 2022.
4. Myelodysplastic Syndromes (MDS)
Roxadustat has received Orphan Drug Designation from the FDA for anemia associated with myelodysplastic syndromes. A Phase 3 protocol is being finalized for submission.
5. Emerging Investigational Uses
Research is exploring roxadustat in kidney transplant recipients with early post-transplant anemia, where it has shown promise. Preclinical studies have also demonstrated protective effects against doxorubicin-induced cardiotoxicity and diabetic complications. A Phase 1 trial in hyperphosphatemia is also listed as completed.
How Does Roxadustat Work? (Mechanism of Action)
Here’s where the elegance of roxadustat truly shines.
Most anemia treatments are blunt instruments: you inject recombinant EPO (like epoetin alfa) to directly stimulate the bone marrow, or you infuse intravenous iron to provide the building blocks for hemoglobin.
Roxadustat, by contrast, works upstream, at the level of gene transcription, to activate a coordinated physiological program that your body has used for millions of years to respond to low oxygen levels.
The sequence of events is as follows:
PHD Inhibition: Roxadustat reversibly binds to and inhibits the active site of prolyl hydroxylase domain (PHD) enzymes, particularly PHD2, which is the primary oxygen sensor in cells.
HIF-α Stabilization: Under normal oxygen (normoxia), PHD enzymes hydroxylate specific proline residues on the HIF-α subunit, tagging it for recognition by the von Hippel-Lindau (VHL) protein and subsequent proteasomal degradation. By inhibiting PHD, roxadustat prevents this hydroxylation, allowing HIF-α to accumulate in the cytoplasm.
Nuclear Translocation and Gene Activation: Stabilized HIF-α translocates to the nucleus, dimerizes with HIF-β (also called ARNT), and forms a functional transcription factor. This complex binds to hypoxia response elements (HREs) in the promoter regions of over 100 target genes.
Endogenous EPO Production: The most clinically relevant target gene is EPO. Unlike recombinant ESAs that flood the bloodstream with supraphysiologic EPO levels, roxadustat induces a more modest, transient, and physiologic EPO peak—comparable to that induced by intermittent hypoxic exposure (such as traveling to high altitude). Peak EPO levels occur within hours of dosing.
Iron Mobilization: This is roxadustat’s secret weapon. HIF stabilization simultaneously suppresses hepcidin, the master iron-regulatory hormone produced by the liver. Lower hepcidin means increased iron absorption from the gut (via ferroportin upregulation) and increased iron release from macrophage stores. In the DOLOMITES trial, roxadustat-treated patients required significantly less IV iron supplementation than those receiving darbepoetin alfa.
Hemoglobin Rise: The combined effect of increased EPO and improved iron availability drives erythropoiesis in the bone marrow. Reticulocytes (young red blood cells) begin appearing in the circulation within days, and a measurable hemoglobin rise is typically seen within 2–3 weeks.
It’s worth noting that HIF regulates many other genes beyond EPO and iron-handling proteins—including VEGF (angiogenesis), GLUT1 (glucose transport), and LDHA (glycolysis)—which is why the safety profile has been scrutinized so heavily.
The pleiotropic effects of HIF activation are a double-edged sword: they contribute to therapeutic benefits but also raise theoretical concerns about tumor growth or vascular complications.
Roxadustat vs. Other Medications
How does roxadustat stack up against the established competition and its fellow HIF-PH inhibitors?
Let’s do a head-to-head.
Roxadustat vs. Erythropoiesis-Stimulating Agents (ESAs: epoetin alfa, darbepoetin alfa)
Route: Roxadustat is oral; ESAs are administered by injection (IV or subcutaneous).
Efficacy: In the DOLOMITES trial, roxadustat achieved a 89.5% Hb response rate vs. 78.0% for darbepoetin alfa, with non-inferiority met. In pooled analyses, roxadustat was superior to placebo in raising hemoglobin and reducing transfusion rates.
Mechanism: ESAs provide exogenous recombinant EPO; roxadustat stimulates endogenous EPO production while simultaneously improving iron mobilization and reducing hepcidin.
Iron Use: Roxadustat consistently reduces the requirement for IV iron. In DOLOMITES, the time to first IV iron use was significantly longer in the roxadustat group.
Cardiovascular Safety: The critical battleground. In NDD-CKD, roxadustat was noninferior to placebo for MACE (HR 1.10; 95% CI 0.96–1.27). In the pooled phase 3 analysis, incident dialysis patients receiving roxadustat had a lower risk of MACE and a trend toward lower all-cause mortality than those receiving epoetin alfa. However, the FDA advisory committee highlighted imbalances in thromboembolic events, leading to the US rejection.
NICE Verdict: “A clinical trial comparing roxadustat with darbepoetin alfa (an ESA) shows that roxadustat works as well as darbepoetin alfa”.
Roxadustat vs. Daprodustat (GSK’s HIF-PHI)
Daprodustat (Duvroq) is roxadustat’s closest rival in the HIF-PHI class. It was approved in Japan in 2020. Phase 3 trials in the US and Europe are ongoing. Compared to roxadustat, daprodustat has a different chemical structure and may have a subtly different safety profile; at the time of writing, roxadustat holds the first-to-market advantage in most global regions.
Roxadustat vs. Vadadustat (Akebia’s HIF-PHI)
Vadadustat suffered a significant setback when a Phase 3 trial in NDD-CKD patients showed an increase in cardiovascular events. It has been filed for FDA approval, but its safety profile has been more clearly problematic than roxadustat’s.
Roxadustat vs. Placebo
In NDD-CKD patients, roxadustat increased hemoglobin by a mean of 1.9 g/dL versus 0.2 g/dL with placebo (treatment difference of 1.7 g/dL; 95% CI, 1.7–1.8 g/dL), while reducing transfusion rates from 20.4 to 6.1 per 100 patient-exposure years.
What Are the Side Effects of Roxadustat?
No sugarcoating here: roxadustat has a complex side effect profile.
The prescribing information for Evrenzo lists the following adverse reactions.
Most Common Adverse Reactions (occurring in ≥10% of patients):
Hypertension (13.9%)
Vascular access thrombosis (12.8%) in dialysis patients
Diarrhea (11.8%)
Peripheral edema (11.7%)
Hyperkalemia (10.9%)
Serious Adverse Events of Special Interest:
Thromboembolic Events: This is the safety signal that most concerns the FDA. Deep vein thrombosis, pulmonary embolism, and vascular access thrombosis occur at higher rates than with placebo or ESAs.
Cardiovascular Events: A 2025 systematic review and meta-analysis of 21 RCTs involving 11,546 patients found that roxadustat was associated with a significantly higher risk of any serious treatment-emergent adverse event (TEAE) compared to control (RR 1.06; 95% CI 1.01–1.11; P=0.01). Hypertension was significantly increased (RR 1.13; 95% CI 1.01–1.26; P=0.03), and withdrawal due to adverse events was doubled (RR 2.02; 95% CI 1.56–2.62; P<0.0001).
Paradoxical Benefit? Remarkably, the same meta-analysis found that all-cause mortality was significantly lower in the roxadustat group (RR 0.56; 95% CI 0.41–0.75; P=0.0001). This finding—a potential mortality benefit despite increased adverse events—has generated intense debate and underscores the need for further research.
Thyroid Function Effects: Roxadustat has been shown to suppress TSH and FT4 levels, producing a biochemical picture that can mimic central hypothyroidism. A study in hemodialysis patients found that roxadustat significantly lowered TSH and FT4 (all P<0.001) and reduced total cholesterol and LDL-C levels. Patients on roxadustat should have their thyroid function and cholesterol levels checked regularly.
Hepatic Impairment: Roxadustat requires dose adjustment in patients with moderate hepatic impairment (Child-Pugh Class B) and is not recommended in those with severe hepatic impairment (Child-Pugh Class C).
It’s essential to put these risks in context. CKD patients already have elevated baseline cardiovascular risk.
The real-world post-marketing surveillance study in Japan (n=2,084) concluded that roxadustat safety was “demonstrated in real-world clinical settings” and that “no new safety concerns were identified”.
Still, the FDA’s concerns remain unresolved in the US market, and a large Phase 4 post-marketing study (10,000 patients) has been proposed to assess whether a lower dose can mitigate thrombotic risk while preserving efficacy.
Roxadustat Dosage and Administration
Roxadustat is supplied as film-coated tablets in strengths of 20 mg, 50 mg, 70 mg, 100 mg, and 150 mg. The oral route is one of its greatest assets.
Starting Dose (ESA-Naive Patients):
Dialysis-Dependent CKD: 70 mg three times weekly for patients weighing 45–<60 kg, or 100 mg three times weekly for those ≥60 kg. Some guidelines list 100 mg (45–60 kg) or 120 mg (≥60 kg) as alternative starting regimens.
Non-Dialysis-Dependent CKD: 50 mg three times weekly for patients weighing 40–<60 kg, or 70 mg three times weekly for those ≥60 kg. For non-dialysis CKD stage 5 patients, starting doses may be escalated to 70 mg (40–<60 kg) or 100 mg (≥60 kg) three times weekly.
Converting from ESAs:
The conversion is based on the average prescribed ESA dose over the 4 weeks prior to switching. For example, a patient receiving darbepoetin alfa at less than 25 mcg/week would start roxadustat at 70 mg three times weekly. Detailed conversion tables are provided in the SmPC.
Dosing Schedule:
Tablets are taken three times per week, NOT on consecutive days—typically Monday/Wednesday/Friday or Tuesday/Thursday/Saturday. Roxadustat can be taken with or without food, and dialysis patients can take their dose at any time before or after a dialysis session.
Dose Titration:
Hemoglobin should be monitored every 2 weeks until stable within the target range of 10–12 g/dL, then every 4 weeks thereafter. Dose adjustments are made every 4 weeks based on hemoglobin level and the change in hemoglobin over the preceding 4 weeks.
The dose ladder ranges from 20 mg to 200 mg per dose, with an upper limit of 2.5 mg/kg per dose.
If a dose is missed, it should NOT be made up—simply resume the regular schedule.
Compounding Guidelines for Roxadustat Formulations
For compounding pharmacists, it’s critical to understand that roxadustat is a proprietary small molecule covered by a patent, and compounding from bulk API is rarely, if ever, indicated outside of a legitimate clinical trial or a specific regulatory framework.
Roxadustat tablets are available in approved, standardized doses, and extemporaneous compounding is not a routine practice in clinical care.
That said, here is what you need to know from a pharmaceutical science perspective:
Physical Properties: Roxadustat API is an off-white to light yellow crystalline powder. It is the free acid form (molecular weight 352.34 g/mol, CAS 808118-40-3). It is practically insoluble in water but soluble in organic solvents like DMSO and ethanol.
Stability: Store at controlled room temperature (20°C to 25°C) with protection from light and moisture. The commercially available capsules contain excipients, including lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, povidone, and magnesium stearate, and are filled with these excipients.
Handling: Roxadustat is not listed as a hazardous drug on the current NIOSH list, but standard precautions for handling pharmaceutical powders should be observed.
Regulatory Status: In regions where roxadustat is approved, compounding it from API would raise significant regulatory and legal issues unless conducted under an appropriate investigational or special access framework.
Look-Alike/Sound-Alike Warning: There is a risk of confusion with roxithromycin (an antibiotic). Pharmacy systems should include tall-man lettering and barcode verification.
Roxadustat Precautions and Drug Interactions
This section is essential for anyone prescribing or taking roxadustat.
The drug is a substrate, inhibitor, and inducer of multiple metabolic enzymes and transporters, making it a veritable minefield of potential pharmacokinetic interactions.
CYP2C8 and UGT1A9 Substrates:
CYP2C8 and UGT1A9 primarily metabolize Roxadustat. Co-administration with gemfibrozil (a strong inhibitor of CYP2C8 and OATP1B1) increased the AUC of roxadustat by 2.3-fold.
Probenecid (a UGT and OAT inhibitor) had a similar effect.
Hemoglobin should be monitored carefully when starting or stopping these drugs, and the roxadustat dose should be adjusted accordingly.
Statins (CRITICAL INTERACTION):
Roxadustat is a potent inhibitor of the drug transporters BCRP and OATP1B1. These transporters are responsible for the hepatic uptake and intestinal efflux of statins. The clinical implications are profound:
Co-administration with rosuvastatin increased rosuvastatin AUC by 2.9-fold and Cmax by 4.5-fold.
Co-administration with simvastatin increased simvastatin AUC by 1.8-fold, and its active metabolite (simvastatin acid) AUC by 1.9-fold and Cmax by 2.8-fold.
Co-administration with atorvastatin increased atorvastatin AUC by 2.0-fold.
The prescribing information states explicitly: “When co-administered with roxadustat, consider this interaction, monitor for adverse reactions associated with statins and for the need for statin dose reduction”. Physiologically-based pharmacokinetic (PBPK) modeling confirms these findings and suggests that roxadustat nearly doubles to triples statin exposure in both healthy volunteers and CKD patients.
Phosphate Binders:
Co-administration with sevelamer carbonate reduced the AUC of roxadustat by 67% and its Cmax by 66%. Calcium acetate reduced AUC by 46% and Cmax by 52%. Roxadustat can form a chelate with multivalent cations. It should be administered at least 1 hour before or 2 hours after phosphate binders.
Thyroid Function Monitoring:
Multiple case reports and observational studies have documented that roxadustat can suppress TSH and FT4 levels, sometimes profoundly. This effect appears reversible upon discontinuation. Regular thyroid function testing is recommended for all patients on roxadustat.
Contraindications:
Hypersensitivity to roxadustat or any excipients
Pregnancy and breastfeeding (no adequate human data; animal studies show reproductive toxicity)
Severe hepatic impairment (Child-Pugh Class C)
Caution in:
Patients with a history of thromboembolic disease, myocardial infarction, or stroke
Patients with uncontrolled hypertension
Patients with seizure disorders (HIF activation may theoretically lower seizure threshold)
Concomitant use of strong CYP2C8 inhibitors (e.g., gemfibrozil, clopidogrel) or inducers (e.g., rifampicin)
Concomitant use of strong UGT1A9 inhibitors (e.g., probenecid, mefenamic acid)
How Long Does Roxadustat Take to Work?
This depends on how you define “work.”
Let’s break it down chronologically:
Hours: After a single oral dose, roxadustat reaches peak plasma concentration (Cmax) at approximately 2 hours in the fasted state. The primary pharmacodynamic effect—a rise in endogenous EPO—begins within hours. Using a sigmoidal Hill equation model, the concentration at half-maximum EPO effect is 10–36 µg/mL, with an effect bisection time of 10–17 hours, which corresponds closely to the natural half-life of EPO. In other words, your body starts pumping out its own EPO almost immediately, just like it would if you suddenly found yourself at 15,000 feet above sea level.
Days: Reticulocytosis—the appearance of young, newly minted red blood cells in the circulation—can be detected within days of starting therapy. Steady-state plasma concentrations of roxadustat are achieved within 1 week (3 doses) with minimal accumulation.
Weeks: The clinically meaningful endpoint—a rise in hemoglobin—has a slightly variable timeline. In a Phase 2 trial of incident dialysis patients, a hemoglobin response (defined as an increase of ≥1.0 g/dL) was achieved in 96% of subjects, with a median time to response of just 3 weeks. Titrated doses increased mean hemoglobin by ≥2.0 g/dL within 7 weeks. In head-to-head studies with epoetin-α, roxadustat achieved target hemoglobin after a median of 9 weeks, compared with 19 weeks with epoetin-α. In a real-world Pakistani study, 87.3% of patients reached the target hemoglobin level (≥10 g/dL) within 6 weeks.
Months: The hemoglobin effect is not just rapid—it’s durable. In the DOLOMITES trial, roxadustat maintained hemoglobin levels for up to 2 years without evidence of tachyphylaxis. The pharmacodynamic model suggests that the rise in hemoglobin is effectively irreversible during treatment, reflecting the natural lifespan of a red blood cell (63–112 days).
Global Sourcing Tips for Roxadustat API
For pharmaceutical manufacturers, traders, and product developers, sourcing high-quality roxadustat active pharmaceutical ingredient (API) demands an understanding of the regulatory landscape, key global manufacturers, and critical quality attributes. Here’s your blueprint.
Critical Quality Attributes:
Polymorph Control: The crystalline form of roxadustat can affect solubility and bioavailability. Ensure your supplier provides XRPD (X-ray powder diffraction) data confirming the correct polymorphic form.
Particle Size Distribution (PSD): PSD is critical for content uniformity in the finished dosage form. Specify a D90 of 50–100 µm for direct-compression blends, or tighter limits if needed for your specific formulation.
Residual Solvents: Review the supplier’s residual solvent profile carefully, as the synthesis may involve Class 2 solvents (e.g., dichloromethane, methanol, toluene, acetonitrile). All must meet ICH Q3C limits.
Impurity Profile: The API should be tested against the reference listed drug (RLD) for related substances. Total impurities are generally controlled at ≤1.0%, with any single unspecified impurity ≤0.10%.
Microbiological Quality: For an oral solid dosage form, the API should meet the microbial limits specified in harmonized pharmacopeias: TAMC ≤ 10³ CFU/g, TYMC ≤ 10² CFU/g, and the absence of E. coli.
Supply Chain Integrity:
Given the relatively small number of qualified suppliers and the high value of bulk roxadustat APIs, supply chain security is paramount.
Always request a recent GMP certificate, a site master file (SMF), and an audit report from a recognized third party.
Sourcing from a distributor rather than directly from the manufacturer requires full traceability back to the original manufacturer, including batch-specific certificates of analysis and the original manufacturer’s documentation.
Counterfeit HIF-PHIs have not been a major issue to date, but as the market expands and other HIF-PHIs gain approval, the risk will rise.
Documentation Package:
For regulatory submission, you’ll need:
DMF Open Letter (or Letter of Access, LOA) from the DMF holder
Complete Module 3.2.S (drug substance) technical package, including characterization, manufacturing process description, process validation, and impurity fate and purge data
Three consecutive commercial-scale batch analyses
ICH-compliant long-term (25°C/60% RH), intermediate (30°C/65% RH), and accelerated (40°C/75% RH) stability data from the first three commercial batches
At minimum, 24 months of long-term and 6 months of accelerated stability data at the time of filing, with a commitment to continue through the proposed retest period
Sourcing the roxadustat API is a strategic investment.
Your supplier’s quality management system, regulatory compliance, and supply reliability directly affect the safety, efficacy, and time-to-market of your finished drug product.
Do not rush this step.
Conclusion
Roxadustat stands at a fascinating crossroads in medical history.
It’s a drug that earned a Nobel Prize for its scientific underpinnings, became the world’s first approved oral HIF-PH inhibitor, and is now helping hundreds of thousands of CKD patients in over 40 countries break free from the tyranny of injectable ESAs and IV iron.
It has improved hemoglobin levels, reduced transfusion requirements, and, in some analyses, suggested a mortality benefit that traditional therapies have never convincingly demonstrated.
And yet, it’s a drug that the FDA—the most influential drug regulator on the planet—has, as of 2026, declined to approve.
The cardiovascular safety signal in the US regulatory review was judged too uncertain and too risky to greenlight without another large clinical trial.
This divergence between the US and the rest of the world is not unprecedented (think aducanumab for Alzheimer’s, approved in the US while rejected elsewhere at the same time). Still, it does force clinicians, patients, and policymakers into uncomfortable conversations about acceptable risk and unmet need.
If you’re a patient outside the US, roxadustat could be a viable oral option—especially if you’re not yet on dialysis, your iron stores are adequate but difficult to manage with IV supplementation, or you want to avoid injections.
If you’re a clinician, the key messages are straightforward: roxadustat is non-inferior to ESAs; it reduces IV iron use; it suppresses hepcidin and LDL; and it requires vigilant monitoring for hypertension, thrombosis, thyroid function, and statin interactions.
The story of roxadustat is far from over. With active Phase 3 trials in MDS, completed Phase 1 work in hyperphosphatemia, and a steady stream of real-world evidence accumulating from post-marketing surveillance in Japan and Europe, this molecule will continue to evolve.
The proposed 10,000-patient post-marketing safety study may eventually unlock the US market.
Until then, the rest of the world will keep generating data, refining protocols, and learning how best to harness the HIF pathway for therapeutic benefit.
Share this guide with a colleague or a fellow patient who’s trying to make sense of their treatment options. Bookmark it. Come back to it. Roxadustat is a complex, nuanced drug—but you no longer have to navigate that complexity alone.
Disclaimer:
This content is for informational purposes only and is intended for business-to-business communication within the pharmaceutical industry. It is not intended as medical advice. The manufacture, import, and use of API must comply with all applicable laws and regulations in the relevant country or region.
This blog post is informational only and does not constitute medical advice.
Always consult a healthcare professional before starting any new medication or treatment.
